BioMarin Pharmaceutical Inc. (BMRN) announced encouraging results from an ongoing phase I/II study on its oncology candidate BMN 673. BioMarin presented the data at the European Cancer Congress in the Netherlands. The study is evaluating BMN 673 in patients suffering from solid tumors.
Updated data from the study revealed a confirmed RECIST (Response Evaluation Criteria in Solid Tumors) response rate of 50% in germline BRCA (gBRCA) patients with breast cancer who were treated with the 1mg/day dosage of BMN 673. We note that this is the selected dosage of the candidate for its upcoming phase III study.
Moreover, updated results from the phase I/II demonstrated that the overall benefit response rate in the gBRCA patients on being treated with the 1mg/day dosage of BMN 673 was 86%. Furthermore, BMN 673 was found to be well tolerated in the phase I/II study.
The company intends to initiate a phase III study on BMN 673 (as a monotherapy) in the gBRCA indication shortly. The primary goal of the study is to compare progression-free survival of patients in the BMN 673 arm with those treated with protocol-specified physicians' choice. The study also intends to assess objective response rate, overall survival, safety and the pharmacokinetics of the candidate.
BMN 673 is one of the many interesting pipeline candidates at BioMarin. The successful development and commercialization of the robust pipeline will help drive long-term growth at BioMarin, which currently has four marketed products.
BioMarin currently carries a Zacks Rank #3 (Hold). Currently, companies which look attractive include Actelion Ltd. (ALIOF), Mylan Inc. (MYL) and Actavis, Inc. (ACT). Actelion carries a Zacks Rank #1 (Strong Buy), while Mylan and Actavis are Zacks #2 Ranked (Buy) stocks.
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment